News

The treatment represents the first approved treatment that directly targets sickle hemoglobin polymerization.

In a Dutch population, the prevalence of MMD increased with older age, lower spherical equivalent of refractive error, and higher axial length.

Cardiologists have utilized new technologies during the COVID-19 pandemic.

TARGET-NASH as now expanded into European centers.

With the concept of a “twindemic” becoming more realistic than ever, experts are stressing that preventive practices, and vaccination, address both flu and COVID-19.

Data on humidity levels in 48 states for over 12 years were featured in the study.

Findings from the SWAY trial highlight a pressing need for varying and more personalized treatment methods for patients.

Topical pimecrolimus 1% treatment had unsatisfactory results, while combination microneedling and topical pimecrolimus treatment showed a favorable outcome.

Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.

TAK-755, a recombinant ADAMTS13, is examined for its therapeutic benefit to patients with sickle cell disease and patients with cTTP.

Prominent dermatologists detail how a biased literature, a lack of education, accessibility issues, and historical wrongdoings have all influenced the study of skin of color.

Investigators believe this could be a good option for patients who did not respond to a first-line biologic, though further research is required.

The treatment resulted in a significant reduction of proteinuria from baseline in 34% of trial participants.

Investigators added that clinical condition at the time of vaccination and biologic treatment did not influence the humoral response in the enrolled patients.

Data show a total absence of influenza-related hospitalization and mortality during the 2020 - 2021 influenza season in Canada.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.

The approval represents the first ever treatment for the disease in patients aged 2 years and older.

Investigators hypothesized that nearly 30% of children in Bnei Brak were infected with influenza during the 2018-2019 outbreak.

Eli Lilly and Company is expected to apply for a Biologics License Application in the first half of 2022.

Data show the weighted influenza vaccination rate among pregnant women was 54.5%, with one third not having a usual source of care.

Investigators suggest that improvements to care could be made based on experiences and recommendations from patients with chronic hand eczema.

The enrollment distribution was consistent by ethnicity over the course of 18 years, with no change in diversity over time despite there being an increase in the UK in the minority population.

Half of all cases of vitiligo occur in childhood, and accessibility to therapy has been an ongoing issue.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored to each unique profile.

Biologics account for significant healthcare-related costs for patients with either ulcerative colitis or Crohn’s disease.

After 2 months of voxelotor treatment, all patients with sickle cell anemia perceived global improvement, but peak VO2 did not change in 8 of 9 patients.

Data show most patients (60.3%) with sickle cell disease achieved a Hb increase of >1 g/dL during the follow-up period.